



The life sciences cluster organisation for London with reach across the UK

DIAGNOSTICS

Please get in touch to find out how we can help with tailored support, including:

- university/NHS research collaborations
- evidence generation & regulatory guidance
- commercialisation expertise
- investment
- finding R&D space
- community networking

Contact: office@medcityhq.com

medcityhq.com

[LinkedIn](#) [Twitter: @MedCityHQ](#)

[Newsletter](#)



DEVELOPING YOUR DIAGNOSTIC IN THE UK

MedCity helps companies grow in one of the world's leading centres for investment, R&D and commercialisation of healthcare diagnostics. We are embedded in the London ecosystem with connections across the UK and globally.

UK MARKET SNAPSHOT

£3 bn

spend by NHS on MedTech

70%

NHS clinical decisions based on in vitro diagnostics

£20.4 bn

Turnover in the MedTech sector

150

new NHS diagnostics hubs

£920 m

NIHR funding for diagnostics



“The UK has all the components to be truly world-leading in diagnostics – we have one solid organisational structure in the NHS and some of the best minds in academia and patient care”

– Professor George Hanna, Clinical Lead, NIHR London In-Vitro Diagnostics Co-operative

SUB SECTORS OVERVIEW



Data & Digital Solutions: London is the leading location in Europe for AI and Bioinformatics talent, fuelling diagnostics development supported by access to patient datasets through Health Data Research hubs in London and beyond.



InVitro Diagnostics and Diagnostic Services: 91% of UK IVD businesses sell globally, supported by a world-leading regulatory system.



Diagnostic Equipment: MedTech forms the largest of the UK's core healthcare segments, with strong investor activity and R&D expertise centred in London.

CHALLENGES

The path to commercialisation for diagnostics innovators is often hampered by lack of collaboration between industry, academia, and clinicians. This makes it costly and time-consuming for companies to develop their technology and generate appropriate evidence to gain regulatory approval.

OPPORTUNITIES

The COVID-19 pandemic provided evidence of the importance of diagnostics, and the huge market potential. The UK, and London in particular, has emerged at the forefront of the sector, thanks to intensive investment from private and public sectors, academic and research excellence, world-leading regulatory strategy, and a universal healthcare system allowing access to patient data and a unified approach to clinical trials.

ACCESS THROUGH MEDCITY

As a neutral player with key relationships across the life sciences ecosystem, MedCity assesses the needs of diagnostics SMEs and connects them with investors, experts at leading universities, industry partners, charity research organisations, and health service providers to accelerate development and adoption.

HOW MEDCITY HELPS DIAGNOSTICS COMPANIES

MedCity Diagnostics Growth Hub is a ‘one stop shop’ for diagnostics and medtech companies to access all the support they need to flourish, from collaboration for early research to evaluation for later-stage

MEDCITY DIAGNOSTICS GROWTH HUB OFFERS:

- 
UNIVERSITY NHS COLLABORATIONS Working closely with London’s leading universities and NHS agencies, we arrange collaborations with companies requiring development support.
- 
EVIDENCE GENERATION & REGULATORY NAVIGATION We are world-leading experts in clinical validation and evidence generation, including data-driven real world evidence. This is especially relevant as new 2022 EU IVD regulations will demand stronger evidence of performance and validity.
- 
COMMERCIALISATION EXPERTISE Our wide-reaching experience of commercialisation pathways in diagnostics subsectors, has helped many companies build business.
- 
ACCESS TO INVESTMENT MedCity Investment Hub works with an Angel network and VC funds to connect companies seeking funding with investors.
- 
ACCESS TO R&D SPACE We help companies find laboratory and work space through our network of lab providers.
- 
MEDCITY COMMUNITY Our online community platform offers peer-to-peer networking, events and bespoke support from MedCity team experts.



CASE STUDIES: ACCELERATING INNOVATION & BUSINESS GROWTH

DIAGNOSTICS AI

Machine learning to monitor diagnostic processes

Diagnostics AI came to MedCity wanting help to: (1) map the existing laboratory processes that Diagnostics AI could automate/replace (2) Acquire laboratory regulatory certification (3) Cement relationships with university collaborators.

KEY OUTCOMES



Grant funding secured
Company expansion



Production scaled up, from 10s of samples to 1000s per day

“Medcity were very helpful in cementing our commercial and technical relationship with Kings College London. This boosted our integraton into the NHS ecosystem, allowing us to achieve regulatory compliance and map our system to internal NHS standards.” – Simon Bengen, CEO

INNERSIGHT

Imaging-based surgical planning software

Innersight came to MedCity to seek academic collaborators. They wanted to ensure Innersight’s working software was up-to-date with the cutting-edge approaches used in academia, and to show academics what’s required to convert promising research results into high quality medical devices.

KEY OUTCOMES



Funding secured
Revenue generation



Long-term collaboration with UCL translational imaging group; technology validation

“We are extremely grateful to MedCity for awarding us and our collaborators with Collaborate to Innovate* funding. It provided us with a wonderful opportunity to ensure our technology was in line with the latest research.”


– Eion Hyde, Founder

* Collaborate to Innovate: MedCity programme facilitating collaborative research projects supported by external funding

EXAMPLES OF OUR DIAGNOSTICS CAPABILITIES

MedCity Diagnostics Growth Hub partners are world-leading diagnostics evaluation & translational science centres. All centres work in multiple modalities and disease areas. Selected focus areas include:

- **NIHR London In Vitro Diagnostics Cooperative:** Experts in evaluating diagnostics and medtechs, focused on oncology, acute medicine & critical care, infectious diseases; primary & community care
- **Imperial College London; Imperial College Health Partners:** Expertise in bioengineering, chemistry, imaging, medical devices, metabolomics, patient safety and clinical decision-making
- **UCL; UCLPartners:** AI and ML, computational modeling, imaging, in vitro diagnostics, lab assays, omics, VR/AR; economic evaluation and market access/NHS implementation
- **Queen Mary's:** DERI and the QMUL Genome Centre brings together units focusing on AI omics, AI for drug discovery, cancer detection, diagnosis and prevention, medical image computing, and neurology
- **Kings College London; Kings Health Partners:** Genetic testing, biomarkers and co-diagnostics for a range of autoimmune, inflammatory, infectious and neoplastic diseases
- **NIHR North West London Clinical Reseach Network:** cancer, cardiovascular diseases, diabetes, gastroenterology, hematology, metabolic disorders, musculoskeletal disorders, neurodegeneration, ophthalmology, primary care, reproductive health, respiratory disorders, stroke and trauma
- **Francis Crick Institute:** Biomarker discovery (including high-throughput proteomic approaches), personalised medicine, novel imaging technologies, high-throughput screening, flow cytometry, and advanced sequencing techniques
- **Health Service Laboratories:** Cytometry, genetics, haematology, histopathology, immunology, microbiology, parasitology, and specialist biochemistry
- **Discover-NOW:** Real-world evidence studies, retrospective RWD studies, clinical trials, real-time validation of devices
- **Insight Health Data Research Hub:** Ophthalmology; disease diagnosis and personalised healthcare provided by large-scale datasets and advanced analytics
- **Data-CAN:** Real-time' cancer data from the NHS as a surrogate marker for pharmaceutical and digital innovation relating to cancer therapeutics
- **Health Innovation Network (HIN):** diabetes, musculoskeletal disorders, cardiovascular disorders using innovations in AI and other technologies
- **Asthma UK and British Lung Foundation:** Allergy and asthma: airway inflammation and function, environment and infection, genetics and epigenetic, IgE structure, function and regulation, and immunomodulation



MEDCITY DIAGNOSTIC GROWTH HUB PARTNERS

A collection of logos for the partner organizations of the MedCity Diagnostic Growth Hub, arranged in a grid. The logos include: NIHR London In Vitro Diagnostics Co-operative, Imperial College London, King's College London, UCL, UCLPartners, Imperial College Health Partners, Queen Mary University of London, The Francis Crick Institute, HIN Health Innovation Network South London, Discover-NOW Health Data Research Hub for Real World Evidence, Asthma UK, British Lung Foundation, NIHR Clinical Research Network North West London, INSIGHT Health Data Research Hub, and Health Services Laboratories.

DID YOU KNOW? MedCity Diagnostics Growth Hub is an evaluation partner for the NHS Accelerated Access Collaborative (AAC), providing independent peer review of AI technologies. Find out more [here](#).